JP2019108391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019108391A5 JP2019108391A5 JP2019043933A JP2019043933A JP2019108391A5 JP 2019108391 A5 JP2019108391 A5 JP 2019108391A5 JP 2019043933 A JP2019043933 A JP 2019043933A JP 2019043933 A JP2019043933 A JP 2019043933A JP 2019108391 A5 JP2019108391 A5 JP 2019108391A5
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pharmaceutical composition
- scarring
- hyperpigmentation
- skin inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773778P | 2013-03-06 | 2013-03-06 | |
| US61/773,778 | 2013-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157337A Division JP6496788B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019108391A JP2019108391A (ja) | 2019-07-04 |
| JP2019108391A5 true JP2019108391A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP6672499B2 JP6672499B2 (ja) | 2020-03-25 |
Family
ID=50389505
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157337A Expired - Fee Related JP6496788B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2019043933A Expired - Fee Related JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157337A Expired - Fee Related JP6496788B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20140256685A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2964214A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6196328B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102223384B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107714683A (cg-RX-API-DMAC7.html) |
| AR (1) | AR095035A1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014226001B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112015021392B1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2899804A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1219661A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2696487C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201446241A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014138046A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040145T2 (hu) * | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| SG11201406629VA (en) * | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| EP2850058B1 (en) | 2012-05-16 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| AU2014226001B2 (en) * | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| KR102313757B1 (ko) * | 2013-07-16 | 2021-10-18 | 알러간, 인코포레이티드 | 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 |
| BR112016001106A8 (pt) | 2013-07-18 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| US9920013B2 (en) | 2014-01-29 | 2018-03-20 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| KR20170005121A (ko) | 2014-05-21 | 2017-01-11 | 알러간, 인코포레이티드 | 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체 |
| US10717708B2 (en) * | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| AU2017241767B2 (en) * | 2016-03-28 | 2021-07-22 | Allergan, Inc. | Phenyl urea derivatives as N-formyl peptide receptor modulators |
| WO2017180323A1 (en) * | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| TWI746660B (zh) * | 2016-10-06 | 2021-11-21 | 日商第一三共股份有限公司 | 尿素衍生物及其用途 |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| ES2799098B2 (es) * | 2019-06-10 | 2021-12-10 | Univ Madrid Carlos Iii | Aptameros agonistas del receptor fpr2 y usos de los mismos |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JPS63232846A (ja) | 1987-03-20 | 1988-09-28 | Haruo Ogura | 新規な固定相担体 |
| AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| DE10005275A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Neuartige Glycokonjugate |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| CA2495284A1 (en) * | 2002-09-05 | 2004-03-18 | Neurosearch A/S | Diarylurea derivatives and their use as chloride channel blockers |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| KR20090121832A (ko) * | 2008-05-23 | 2009-11-26 | 인제대학교 산학협력단 | 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물 |
| WO2010056778A1 (en) * | 2008-11-11 | 2010-05-20 | Signum Biosciences, Inc. | Isoprenyl compounds and methods thereof |
| WO2010104306A2 (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2011073918A2 (en) * | 2009-12-16 | 2011-06-23 | Actelion Pharmaceuticals Ltd | Peptides as modulators of fprl1 and/or fprl2 |
| EP2585054A1 (en) * | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| AU2011336973A1 (en) * | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| WO2012109544A1 (en) | 2011-02-11 | 2012-08-16 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US20120329873A1 (en) | 2011-06-17 | 2012-12-27 | Li yong-xin | D-serine for the treatment of visual system disorders |
| EP2731931A1 (en) | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| HUE040145T2 (hu) * | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| EP2814815A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| SG11201406629VA (en) * | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| AU2014226001B2 (en) * | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
| EP2964213B1 (en) * | 2013-03-06 | 2020-11-04 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| KR102313757B1 (ko) * | 2013-07-16 | 2021-10-18 | 알러간, 인코포레이티드 | 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 |
| US20150080466A1 (en) | 2013-09-19 | 2015-03-19 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| BR112016011417A8 (pt) | 2013-11-21 | 2020-05-05 | Allergan Inc | derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos |
| KR20170005121A (ko) * | 2014-05-21 | 2017-01-11 | 알러간, 인코포레이티드 | 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체 |
-
2014
- 2014-03-04 AU AU2014226001A patent/AU2014226001B2/en not_active Ceased
- 2014-03-04 HK HK16107753.4A patent/HK1219661A1/zh unknown
- 2014-03-04 KR KR1020157024039A patent/KR102223384B1/ko not_active Expired - Fee Related
- 2014-03-04 US US14/196,155 patent/US20140256685A1/en not_active Abandoned
- 2014-03-04 BR BR112015021392-8A patent/BR112015021392B1/pt not_active IP Right Cessation
- 2014-03-04 WO PCT/US2014/020273 patent/WO2014138046A1/en not_active Ceased
- 2014-03-04 RU RU2015134778A patent/RU2696487C2/ru active
- 2014-03-04 CN CN201711029910.2A patent/CN107714683A/zh active Pending
- 2014-03-04 CA CA2899804A patent/CA2899804A1/en not_active Abandoned
- 2014-03-04 CA CA3114477A patent/CA3114477A1/en not_active Abandoned
- 2014-03-04 JP JP2015561540A patent/JP6196328B2/ja not_active Expired - Fee Related
- 2014-03-04 CN CN201480011861.8A patent/CN105007908B/zh not_active Expired - Fee Related
- 2014-03-04 KR KR1020217005968A patent/KR20210024691A/ko not_active Ceased
- 2014-03-04 EP EP14713302.9A patent/EP2964214A1/en not_active Withdrawn
- 2014-03-04 CA CA3114347A patent/CA3114347A1/en not_active Abandoned
- 2014-03-04 BR BR122017004256-4A patent/BR122017004256A2/pt not_active Application Discontinuation
- 2014-03-06 TW TW103107759A patent/TW201446241A/zh unknown
- 2014-03-06 AR ARP140100733A patent/AR095035A1/es unknown
-
2017
- 2017-04-18 US US15/490,127 patent/US10434112B2/en not_active Expired - Fee Related
- 2017-08-17 JP JP2017157337A patent/JP6496788B2/ja not_active Expired - Fee Related
- 2017-08-17 JP JP2017157336A patent/JP6496787B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-22 HK HK18110777.8A patent/HK1251185A1/zh unknown
-
2019
- 2019-03-06 AU AU2019201538A patent/AU2019201538B2/en not_active Ceased
- 2019-03-11 JP JP2019043933A patent/JP6672499B2/ja not_active Expired - Fee Related
- 2019-09-10 US US16/566,682 patent/US10799518B2/en not_active Expired - Fee Related
-
2020
- 2020-09-22 US US17/028,440 patent/US20210008085A1/en not_active Abandoned
- 2020-09-22 US US17/028,416 patent/US20210000846A1/en not_active Abandoned
-
2021
- 2021-05-18 AU AU2021203183A patent/AU2021203183A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li | Renoprotective effects of vitamin D analogs | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| AR095035A1 (es) | Uso de un agonista del receptor 2 del péptido formilo para la preparación de una composición farmacéutica para el tratamiento de inflamación y enfermedades dérmicas | |
| WO2018218070A3 (en) | COVALENT INHIBITORS OF KRAS | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| JP2013522326A5 (cg-RX-API-DMAC7.html) | ||
| WO2015130842A3 (en) | Ether compounds for treatment of complement mediated disorders | |
| MX364205B (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades. | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2010006189A3 (en) | Small-molecule inhibitors of hif and angiogenesis | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| US8475775B1 (en) | Retinoids and use thereof | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| WO2014126944A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| JP2014511393A5 (cg-RX-API-DMAC7.html) | ||
| MX2014005075A (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| MY195058A (en) | Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same | |
| WO2015031109A8 (en) | Inhibition of wnt, tgf beta and hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders | |
| JP2016501219A5 (cg-RX-API-DMAC7.html) | ||
| WO2012112447A3 (en) | Histone deacetylase inhibitors and methods of use thereof | |
| CL2008000554A1 (es) | Compuestos derivados de diaminopirimidina sustituida; metodo de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario, un estado patologico doloroso, un trastorno res |